Evidence map›Paper›PMID 25428261›Full record

ArticleLeukemia2015

Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40-60 years.

J J Cornelissen, J Versluis, J R Passweg, W L J van Putten, M G Manz, J Maertens, H B Beverloo, P J M Valk, M van Marwijk Kooy, P W Wijermans and 19 more

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in Leukemia, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
70citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

70 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Observational
  19. Article
  20. Article

10 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

J J CornelissenDepartment of Hematology, Erasmus University medical center Cancer Institute, Rotterdam, The Netherlands.
J VersluisDepartment of Hematology, Erasmus University medical center Cancer Institute, Rotterdam, The Netherlands.
J R PasswegStem Cell Transplant Team, University Hospital Basel, Basel, Switzerland.
W L J van PuttenHOVON Data Center and Department of Trials and Statistics, Rotterdam, The Netherlands.
M G ManzDivision of Hematology, University Hospital Zürich, Zürich, Switzerland.
J MaertensDepartment of Hematology, University Hospital Gasthuisberg, Leuven, Belgium.
H B BeverlooDepartment of Clinical Genetics, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands.
P J M ValkDepartment of Hematology, Erasmus University medical center Cancer Institute, Rotterdam, The Netherlands.
M van Marwijk KooyDepartment of Internal medicine, Isala Hospital, Zwolle, The Netherlands.
P W WijermansDepartment of Hematology, Haga Hospital, The Hague, The Netherlands.
M R SchaafsmaDepartment of Hematology, Medisch Spectrum Twente, Enschede, The Netherlands.
B J BiemondDepartment of Hematology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
M-C VekemansDepartment of Hematology, Hôpital St Luc, Brussels, Belgium.
D A BreemsDepartment of Hematology, Stuivenberg Hospital, Antwerp, Belgium.
L F VerdonckDepartments of Immunology and Hematology, University Medical Center, Utrecht, The Netherlands.
M F FeyDepartment of Medical Oncology, Inselspital, Bern University Hospital, Bern, Switzerland.
M Jongen-LavrencicDepartment of Hematology, Erasmus University medical center Cancer Institute, Rotterdam, The Netherlands.
J J W M JanssenDepartment of Hematology, VU University Medical Center, Amsterdam, The Netherlands.
G HulsDepartment of Hematology, University Medical Center Groningen, Groningen, The Netherlands.
J KuballDepartments of Immunology and Hematology, University Medical Center, Utrecht, The Netherlands.
T PabstDepartment of Medical Oncology, Inselspital, Bern University Hospital, Bern, Switzerland.
C GrauxDepartment of Hematology, Mont-Godinne, Yvoir, Belgium.
H C SchoutenDepartment of Hematology, University Hospital Maastricht, Maastricht, The Netherlands.
A GratwohlStem Cell Transplant Team, University Hospital Basel, Basel, Switzerland.
E VellengaDepartment of Hematology, University Medical Center Groningen, Groningen, The Netherlands.
G OssenkoppeleDepartment of Hematology, VU University Medical Center, Amsterdam, The Netherlands.
B LöwenbergDepartment of Hematology, Erasmus University medical center Cancer Institute, Rotterdam, The Netherlands.
HOVON
SAKK Leukemia Groups

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The preferred type of post-remission therapy (PRT) in patients with acute myeloid leukemia (AML) in first complete remission (CR1) is a subject of continued debate, especially in patients at higher risk of nonrelapse mortality (NRM), including patients >40 years of age. We report results of a time-dependent multivariable analysis of allogenic hematopoietic stem cell transplantation (alloHSCT) (n=337) versus chemotherapy (n=271) or autologous HSCT (autoHSCT) (n=152) in 760 patients aged 40-60 years with AML in CR1. Patients receiving alloHSCT showed improved overall survival (OS) as compared with chemotherapy (respectively, 57±3% vs 40±3% at 5 years, P<0.001). Comparable OS was observed following alloHSCT and autoHSCT in patients with intermediate-risk AML (60±4 vs 54±5%). However, alloHSCT was associated with less relapse (hazard ratio (HR) 0.51, P<0.001) and better relapse-free survival (RFS) (HR 0.74, P=0.029) as compared with autoHSCT in intermediate-risk AMLs. AlloHSCT was applied following myeloablative conditioning (n=157) or reduced intensity conditioning (n=180), resulting in less NRM, but comparable outcome with respect to OS, RFS and relapse. Collectively, these results show that alloHSCT is to be preferred over chemotherapy as PRT in patients with intermediate- and poor-risk AML aged 40-60 years, whereas autoHSCT remains a treatment option to be considered in patients with intermediate-risk AML.

Indexed as

AdultAntineoplastic AgentsDisease-Free SurvivalFemaleHematopoietic Stem Cell TransplantationHumansLeukemia, Myeloid, AcuteMaleMiddle AgedMultivariate AnalysisProportional Hazards ModelsRemission InductionRiskTime FactorsTransplantation ConditioningTransplantation, HomologousAntineoplastic Agents

Identifiers

PMID25428261

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.